Literature DB >> 12435709

In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.

Ellie J C Goldstein1, Diane M Citron, C Vreni Merriam, Yumi A Warren, Kerin L Tyrrell, Helen T Fernandez.   

Abstract

Garenoxacin (BMS 284756) was active against 105 of 108 (97%) recent clinical Gardnerella vaginalis isolates at < or =2 micro g/ml by using the reference agar dilution method for anaerobes. Twenty-eight percent of isolates (31 of 108) were resistant to metronidazole, and 44% were resistant to doxycycline. All were susceptible to clindamycin and ampicillin-sulbactam.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12435709      PMCID： PMC132768          DOI： 10.1128/AAC.46.12.3995-3996.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Understanding the bacterial flora of the female genital tract.

Authors:  B Larsen; G R Monif
Journal:  Clin Infect Dis       Date:  2001-02-09       Impact factor: 9.079

3.  Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis.

Authors:  R M Bannatyne; A M Smith
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

4.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients.

Authors:  H Mikamo; Y Sato; Y Hayasaki; K Kawazoe; T Tamaya
Journal:  Chemotherapy       Date:  1999 May-Jun       Impact factor: 2.544

6.  Therapy of bacterial vaginosis.

Authors:  P E Hay
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

7.  Gardnerella vaginalis isolated from patients with bacterial vaginosis and from patients with healthy vaginal ecosystems.

Authors:  A A Aroutcheva; J A Simoes; K Behbakht; S Faro
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

8.  Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.

Authors:  N Kato; H Kato; K Tanaka-Bando; K Watanabe; K Ueno
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

9.  Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.

Authors:  E J Goldstein; D M Citron; C E Cherubin; S L Hillier
Journal:  J Antimicrob Chemother       Date:  1993-03       Impact factor: 5.790

10.  In vitro activity of seventeen antimicrobial agents against Gardnerella vaginalis.

Authors:  S Shanker; M Toohey; R Munro
Journal:  Eur J Clin Microbiol       Date:  1982-10       Impact factor: 3.267
View more
  9 in total

Review 1.  Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis.

Authors:  Ronald F Lamont; Chia-Ling Nhan-Chang; Jack D Sobel; Kimberly Workowski; Agustin Conde-Agudelo; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2011-04-02       Impact factor: 8.661

2.  Gardnerella vaginalis population dynamics in bacterial vaginosis.

Authors:  D W Hilbert; J A Schuyler; M E Adelson; E Mordechai; J D Sobel; S E Gygax
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-14       Impact factor: 3.267

3.  In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?

Authors:  Giuseppe Togni; Valeria Battini; Anna Bulgheroni; Federico Mailland; Maurizio Caserini; Werner Mendling
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

Review 4.  Bacterial vaginosis, Atopobium vaginae and nifuratel.

Authors:  Franco Polatti
Journal:  Curr Clin Pharmacol       Date:  2012-02-01

5.  Antibiotic susceptibility of Atopobium vaginae.

Authors:  Ellen De Backer; Rita Verhelst; Hans Verstraelen; Geert Claeys; Gerda Verschraegen; Marleen Temmerman; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2006-03-16       Impact factor: 3.090

6.  Draft Genome Sequence of a Metronidazole-Resistant Gardnerella vaginalis Isolate.

Authors:  Jessica A Schuyler; Sean G Chadwick; Eli Mordechai; Martin E Adelson; Scott E Gygax; David W Hilbert
Journal:  Genome Announc       Date:  2015-09-03

Review 7.  Advances in the Prevention of Infection-Related Preterm Birth.

Authors:  Ronald F Lamont
Journal:  Front Immunol       Date:  2015-11-16       Impact factor: 7.561

Review 8.  Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.

Authors:  Werner Mendling; Ernst Rainer Weissenbacher; Stefan Gerber; Valdas Prasauskas; Philipp Grob
Journal:  Arch Gynecol Obstet       Date:  2015-10-27       Impact factor: 2.344

9.  Draft Genome Sequence of a Metronidazole-Resistant Derivative of Gardnerella vaginalis Strain ATCC 14019.

Authors:  Jessica A Schuyler; Eli Mordechai; Martin E Adelson; Scott E Gygax; David W Hilbert
Journal:  Genome Announc       Date:  2015-11-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.